nach oben

Irish Journal of Medical Science (1971 -)

Erschienen in:

01.03.2010 | Review Article

Anaplastic thyroid cancer, tumorigenesis and therapy

verfasst von: J. P. O’Neill, D. Power, C. Condron, D. Bouchier-Hayes, M. Walsh

Erschienen in: Irish Journal of Medical Science (1971 -) | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Anaplastic thyroid cancer (ATC) is a fatal endocrine malignancy. Current therapy fails to significantly improve survival. Recent insights into thyroid tumorigenesis, post-malignant dedifferentiation and mode of metastatic activity offer new therapeutic strategies.

Methods

An extensive literature search of Medline and Pubmed was conducted to include all published reports on ATC. Secondary articles were identified from key paper reference listings.

Conclusions

Significant progress, in the last 5 years, has been made outlining thyroid tumorigenesis and the progression to anaplasia. Continued identification and development of drug therapies is required to counter specific molecular targets responsible for the post-malignant dedifferentiation process and ultimately the fatal neoplastic phenotype.

Are C, Shaha AR (2006) Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 13:453–464. doi:10.1245/ASO.2006.05.042 CrossRefPubMed

Ain KB (1998) Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid 8:715–726. doi:10.1089/thy.1998.8.715 CrossRefPubMed

Albores-Saavedra J, Henson DE, Glazer E et al (2007) Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype-papillary, follicular, and anaplastic: a morphological and epidemiological study. Endocr Pathol 18:1–7. doi:10.1007/s12022-007-0002-z CrossRefPubMed

Kobayashi TK, Asakawa H, Umeshita K et al (1996) Treatment of 37 patients with anaplastic carcinoma of the thyroid. Head Neck 18:36–41. doi:10.1002/(SICI)1097-0347(199601/02)18:1<36::AID-HED5>3.0.CO;2-# CrossRefPubMed

Kim TY, Kim KW, Jung TS et al (2007) Prognostic factors for Korean patients with anaplastic thyroid carcinoma. Head Neck 29:765–772. doi:10.1002/hed.20578 CrossRefPubMed

Sugitani I, Kasai N, Fujimoto Y et al (2001) Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid. World J Surg 25:617–622. doi:10.1007/s002680020166 CrossRefPubMed

Delellis RA (2006) Pathology and genetics of thyroid carcinoma. J Surg Oncol 94:662–669. doi:10.1002/jso.20700 CrossRefPubMed

Saltman B, Singh B, Hedvat CV et al (2006) Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression. Surgery 140:899–905. doi:10.1016/j.surg.2006.07.027 CrossRefPubMed

Wiseman SM, Loree TR, Rigual NR et al (2003) Anaplastic transformation of thyroid cancer: review of clinical, pathologic, and molecular evidence provides new insights into disease biology and future therapy. Head Neck 25:662–670. doi:10.1002/hed.10277 CrossRefPubMed

10.

Wiseman SM, Masoudi H, Niblock P et al (2007) Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Ann Surg Oncol 14:719–729. doi:10.1245/s10434-006-9178-6 CrossRefPubMed

11.

Wiseman SM, Griffith OL, Deen S et al (2007) Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma. Arch Surg 142:727–729

12.

Nikiforova MN, Kimura ET, Gandhi M et al (2003) BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399–5404. doi:10.1210/jc.2003-030838 CrossRefPubMed

13.

Lemoine NR, Mayall ES, Wyllie FS et al (1989) High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 4:159–164PubMed

14.

Quiros RM, Ding HG, Gattuso P et al (2005) Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer 103:2261–2268. doi:10.1002/cncr.21073 CrossRefPubMed

15.

Segev DL, Umbricht C, Zeiger MA (2003) Molecular pathogenesis of thyroid cancer. Surg Oncol 12:69–90. doi:10.1016/S0960-7404(03)00037-9 CrossRefPubMed

16.

Lam KY, Lo CY, Chan KW et al (2000) Insular and anaplastic carcinoma of the thyroid. A 45 year comparative study at a single institution and review of the significance of p53 and p21. Ann Surg 231:329–338. doi:10.1097/00000658-200003000-00005 CrossRefPubMed

17.

Moretti F, Nanni S, Farsetti A et al (2000) Effects of exogenous p53 transduction in thyroid tumor cells with different p53 status. J Clin Endocrinol Metab 85:302–308. doi:10.1210/jc.85.1.302 CrossRefPubMed

18.

LaPerle KM, Jhiang SM, Capen CC (2000) Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas. Am J Pathol 157:671–677

19.

Nakashima M, Takamura N, Namba H et al (2007) RET oncogene amplification in thyroid cancer: correlations with radiation-associated and high grade malignancy. Hum Pathol 38:621–628. doi:10.1016/j.humpath.2006.10.013 CrossRefPubMed

20.

Santoro M, Papotti M, Chiappetta G et al (2002) RET activation and clinicopathologic features in poorly differentiated thyroid tumors. J Clin Endocrinol Metab 87:370–379. doi:10.1210/jc.87.1.370 CrossRefPubMed

21.

Shannon KB, Salmon ED (2002) Chromosome dynamics: new light on Aurora B kinase function. Curr Biol 12:458–460. doi:10.1016/S0960-9822(02)00945-4 CrossRef

22.

Ulisse S, Delcros JG, Baldini E et al (2006) Expression of Aurora kinases in human thyroid carcinoma cell lines and tissues. Int J Cancer 119:275–282. doi:10.1002/ijc.21842 CrossRefPubMed

23.

Sorrentino R, Libertini S, Pallante PL et al (2005) Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J Clin Endocrinol Metab 90:928–935. doi:10.1210/jc.2004-1518 CrossRefPubMed

24.

Lim SC, Lee MS (2002) Significance of E-cadherin/beta-catenin complex and cyclin D1 in breast cancer. Oncol Rep 9:915–928PubMed

25.

Barton MC, Akli S, Keyomarsi K (2006) Deregulation of cyclin E meets dysfunction in p53: closing the escape hatch on breast cancer. J Cell Physiol 209:686–694. doi:10.1002/jcp.20818 CrossRefPubMed

26.

Musgrove EA (2006) Cyclins: roles in mitogenic signaling and oncogenic transformation. Growth Factors 24:13–19. doi:10.1080/08977190500361812 CrossRefPubMed

27.

Fagin JA, Matsuo K, Karmakar A et al (1993) High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91:179–184. doi:10.1172/JCI116168 CrossRefPubMed

28.

Garcia-Rostan G, Tallini G, Herrero A et al (1999) Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res 59:1811–1815PubMed

29.

Wiseman SM, Masoudi H, Niblock P et al (2006) Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. Am J Surg 191:581–587. doi:10.1016/j.amjsurg.2006.02.005 CrossRefPubMed

30.

Rocha AS, Soares P, Fonseca E, Cameselle-Teijeiro J et al (2003) E-cadherin loss rather than beta-catenin alterations is a common feature of poorly differentiated thyroid carcinomas. Histopathology 42:580–587. doi:10.1046/j.1365-2559.2003.01642.x CrossRefPubMed

31.

Garcia-Rostan G, Camp RL, Herrero A et al (2001) Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol 158:987–996PubMed

32.

Hou P, Liu D, Shan Y et al (2007) Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res 13:1161–1170. doi:10.1158/1078-0432.CCR-06-1125 CrossRefPubMed

33.

Garcia-Rostan G, Costa AM, Pereira-Castro I et al (2005) Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res 65:10199–10207. doi:10.1158/0008-5472.CAN-04-4259 CrossRefPubMed

34.

Ensinger C, Spizzo G, Moser P et al (2004) Epidermal growth factor receptor as a novel therapeutic target in anaplastic thyroid carcinomas. Ann NY Acad Sci 1030:69–77. doi:10.1196/annals.1329.009 CrossRefPubMed

35.

Viglietto G, Maglione D, Rambaldi M et al (1995) Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PIGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 11:1569–1579PubMed

36.

Prichard CN, Kim S, Yazici YD et al (2007) Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma. Laryngoscope 117:674–679. doi:10.1097/MLG.0b013e318031055e CrossRefPubMed

37.

Kim S, Prichard CN, Younes MN et al (2006) Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Clin Cancer Res 12:600–607. doi:10.1158/1078-0432.CCR-05-1325 CrossRefPubMed

38.

Kim S, Schiff BA, Yigitbasi OG et al (2005) Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788. Mol Cancer Ther 4:632–640. doi:10.1158/1535-7163.MCT-04-0293 CrossRefPubMed

39.

Hoffman S, Burchert A, Wunderlich A et al (2007) Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines. Endocrine 31:105–113. doi:10.1007/s12020-007-0008-9 CrossRef

40.

Yohoi K, Thaker PH, Yazici S et al (2005) Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model. Cancer Res 65:3716–3725. doi:10.1158/0008-5472.CAN-04-3700 CrossRef

41.

Kim S, Yazici YD, Calzada G et al (2007) Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther 6:1785–1792. doi:10.1158/1535-7163.MCT-06-0595 CrossRefPubMed

42.

Smit JW, Schroder-van der Elst JP, Karperien M et al (2007) Iodide kinetics and experimental (131)I therapy in a xenotransplanted human sodium-iodide symporter-transfected human follicular thyroid carcinoma cell line. J Clin Endocrinol Metab 87:1247–1253. doi:10.1210/jc.87.3.1247 CrossRef

43.

Hsieh YJ, Ke CC, Liu RS et al (2007) Radioiodide imaging and treatment of ARO cancer xenograft in a mouse model after expression of human sodium iodide symporter. Anticancer Res 27:2515–2522PubMed

44.

Lee YJ, Chung JK, Shin JH et al (2004) In vitro and in vivo properties of a human anaplastic thyroid carcinoma cell line transfected with the sodium iodide symporter gene. Thyroid 14:889–895. doi:10.1089/thy.2004.14.889 CrossRefPubMed

45.

Jeong H, Kim YR, Kim KN et al (2006) Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line. Nucl Med Biol 33:875–882. doi:10.1016/j.nucmedbio.2006.07.004 CrossRefPubMed

46.

Presta I, Arturi F, Ferretti E et al (2005) Recovery of NIS expression in thyroid cancer cells by overexpression of Pax8 gene. BMC Cancer 5:80. doi:10.1186/1471-2407-5-80 CrossRefPubMed

47.

Sugawara I, Masunaga A, Itoyama S et al (1995) Expression of multidrug resistance-associated protein (MRP) in thyroid cancers. Cancer Lett 95:135–138. doi:10.1016/0304-3835(95)03878-z CrossRefPubMed

48.

Yasuhisa K, Shin-ya M, Michinori M et al (2007) Mechanism of multidrug recognition by MDR1/ABCB1. Cancer Sci 98:1303–1310. doi:10.1111/j.1349-7006.2007.00538.x CrossRef

49.

Touhey S, O’Connor R, Plunkett S et al (2002) Structure-activity relationship of indomethacin analogues for MRP-1, COX-1 and COX-2 inhibition: identification of novel chemotherapeutic drug resistance modulators. Eur J Cancer 38:1661–1670. doi:10.1016/S0959-8049(02)00128-4 CrossRefPubMed

50.

Brignardello E, Gallo M, Baldi I et al (2007) Anaplastic thyroid carcinoma: clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years. Eur J Endocrinol 156:425–430. doi:10.1530/EJE-06-0677 CrossRefPubMed

51.

Kebebew E, Greenspan FS, Clark OH et al (2005) Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 103:1330–1335. doi:10.1002/cncr.20936 CrossRefPubMed

52.

Pierie JP, Muzikansky A, Gaz RD et al (2002) The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann Surg Oncol 9:57–64. doi:10.1245/aso.2002.9.1.57 CrossRefPubMed

53.

Lang BH, Lo CY (2007) Surgical options in undifferentiated thyroid carcinoma. World J Surg 31:969–977. doi:10.1007/s00268-007-0776-7 CrossRefPubMed

54.

Voigt W, Kegel T, Weiss M et al (2005) Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma. J Cancer Res Clin Oncol 131:585–590. doi:10.1007/s00432-005-0673-0 CrossRefPubMed

Titel: Anaplastic thyroid cancer, tumorigenesis and therapy
verfasst von: J. P. O’Neill
D. Power
C. Condron
D. Bouchier-Hayes
M. Walsh
Publikationsdatum: 01.03.2010
Verlag: Springer-Verlag
Erschienen in: Irish Journal of Medical Science (1971 -) / Ausgabe 1/2010
Print ISSN: 0021-1265
Elektronische ISSN: 1863-4362
DOI: https://doi.org/10.1007/s11845-009-0364-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Anaplastic thyroid cancer, tumorigenesis and therapy

Abstract

Background

Methods

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Background

Methods

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2010

An audit of hip fracture services in the Mater Hospital Dublin 2001 compared with 2006

An evaluation of the range and availability of intensive smoking cessation services in Ireland

Cerebral venous thrombosis presenting as a complication of inflammatory bowel disease

RETRACTED ARTICLE: Magnetic resonance imaging evaluation of intervertebral test spacers: an experimental comparison of magnesium versus titanium and carbon fiber reinforced polymers as biomaterials

Usage of herbal medications in patients undergoing IVF treatment in an Irish infertility treatment unit

Laparoscopic bariatric surgery for morbid obesity: the first hundred cases in an Irish centre

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Update Innere Medizin